What Is Non-Small-Cell Lung Cancer (NSCLC)? Most people who have lung cancer have NSCLC. Although it's serious, treatment can sometimes stop it from getting worse. There are things you can do to ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and carries a lower mortality risk than other forms. The most common risk factor for NSCLC is smoking cigarettes.

This overview provides a thorough review of current treatment approaches for first-line management of nononcogenic addicted non–small cell lung cancer. We also address pertinent clinical ...

In patients with advanced non–small cell lung cancer without actionable genomic alterations, whose tumors progress during or after first-line chemoimmunotherapy, second-line monotherapy with docetaxel ...

Despite advances in drug development, some patients with non-small-cell lung cancer (NSCLC) have suboptimal responses to treatment. The authors of this Review provide an overview of the complexity ...

Among patients with advanced or metastatic non-small cell lung cancer (NSCLC) with actionable genomic alterations, encouraging and durable antitumor activity was observed during treatment with ...

Lung cancer is the leading cause of cancer deaths among both men and women. Small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) are the two main types of lung cancer. Most lung ...

Mesothelioma and non-small cell lung cancer (NSCLC) are two types of cancers. They may have similar symptoms, such as chest pain and difficulty breathing, but there are a few key differences.

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all cases. It develops when abnormal lung cells grow uncontrollably, forming a tumor.

Adagrasib, a KRAS G12C inhibitor, irreversibly and selectively binds KRAS G12C, locking it in its inactive state. Adagrasib showed clinical activity and had an acceptable adverse-event profile in ...